Nancy B. Gordon, MD
Department of Pediatrics, Division of Pediatrics
Present Title & Affiliation
Primary Appointment
Associate Professor, Pediatrics - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1993 | Universidad Central de Venezuela, Luis Razetti School of Medicine, Ciudad Universitaria, Caracas, VE, MD |
Postgraduate Training
| 2006-2009 | Research Fellowship, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2004-2005 | Clinical Fellowship, Solid Tumors, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2001-2004 | Clinical Fellowship, Pediatric Hematology-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 1998-2001 | Pediatric Residency, Driscoll Children's Hospital, Corpus Christi, Texas |
| 1992-1993 | Clinical Internship, Hospital Universitario de Caracas, Universidad Central de Venezuela, Ciudad Universitaria, Caracas |
| 1989-1991 | Clinical Internship, Hospital Carlos J. Bello, Cruz Roja Venezolana, Caracas |
| 1986-1993 | Clinical Residency, Medical Doctor, Universidad Central de Venezuela, "Luis Razetti" School of Medicine, Ciudad Universitaria, Caracas |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Pediatrics - Research, Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2010 - 2020
Instructor, Pediatrics - Research, Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2010 - 2010
Other Professional Positions
Co-Director, Research Training Program for Clinical Fellows, The University of Texas MD Anderson Cancer, 2023 - Present
Director, Research Training Program for Clinical Fellows, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2010 - 2017
Research Associate, Texas Children's Hospital, Houston, Texas, 1996 - 1997
Extramural Institutional Committee Activities
Member, Faculty Wellness Collaborative, The University of Texas MD Anderson Cancer Center, 2026 - Present
Faculty Moderator, Fellows' Research Showcase, The University of Texas MD Anderson Cancer Center, 2026 - Present
Member, Pep Squad Pediatric Wellness Task Force Committee, The University of Texas MD Anderson Cancer Center, 2026 - Present
Chair, Mid-Career Faculty Committee (MCFC), The University of Texas MD Anderson Cancer Center, 2026 - Present
Presentation Organizer, Junior Career Faculty Committee-Fireside Chat Dr. Carin Hagberg, The University of Texas MD Anderson Cancer Center, 2026
Award Reviewer, Margaret L. Kripke Legend Award Committee, The University of Texas MD Anderson Cancer Center, 2026
Member, RFA Pre-review Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Chair, Mid-Term Progression Review Committee, The University of Texas MD Anderson Cancer Center, 2025
Moderator, Fellows' Research Showcase, The University of Texas MD Anderson Cancer Center, 2024
Member, Kiran Kundu TRIUMPH Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Pebble in the Shoe Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Poster Presentation Judge, Graduate Student Research Day (GSRD) 2022, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Pediatrics International Travel Policy for Faculty and Trainees Committee Service, The University of Texas MD Anderson Cancer Center, 2022 - Present
Co-Chair, AI In Human Health Organizer Symposium, The University of Texas MD Anderson Cancer Center, 2022
Leader, Pediatric Team Leaders, The University of Texas MD Anderson Cancer Center, 2022 - Present
Co-Leader, Pediatric Research-Clincal Team, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, CCH Executive Advisory Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Pediatrics Grand Round Organizer Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Pediatrics Sarcoma- Solid Tumor, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Pediatric Grand Round CME-COI Peer Review PEP System, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Division of Pediatrics DEI Committee Service, The University of Texas MD Anderson Cancer Center, 2022 - 2023
Member, 2020 Trainee Research Day | Endowed Fellowship Awards - Academic Review Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Committee Member, Faculty Senate Research Affairs Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2025
Steering Committee Member, Gulf Coast Consortia cluster “Artificial Intelligence in Healthcare”, The University of Texas MD Anderson Cancer Center, 2019 - 2023
Member, MDACC Data and Biospecimen Access Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, Biobank User Group, The University of Texas MD Anderson Cancer Center, 2018 - Present
Member, TissueStation User Group, The University of Texas MD Anderson Cancer Center, 2017 - Present
Member, Pediatrics Imaging Team, The University of Texas MD Anderson Cancer Center, 2017 - Present
Co-Leader, Pediatrics Biospecimen Team, The University of Texas MD Anderson Cancer Center, 2017 - Present
Co-Leader, Pediatrics Sarcoma - Solid Tumor Team, The University of Texas MD Anderson Cancer Center, 2017 - 2022
Member, Special Task Force- XFIT2 (Cross-Functional Intervention and Transformation Team), The University of Texas MD Anderson Cancer Center, 2017 - 2019
Member, Clinical Translational Research Center (CTRC) Working Group, The University of Texas MD Anderson Cancer Center, 2017 - 2018
Faculty Senator, Faculty Senate Representation for the Department of Pediatrics, The University of Texas MD Anderson Cancer Center, 2014 - 2021
Associate Member, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, 2014 - Present
Member, Fellowship Evaluation Committee, The University of Texas MD Anderson Cancer Center, 2014 - Present
Protocol Reviewer, Clinical Research Committee (CRC), The University of Texas MD Anderson Cancer Center, 2011 - Present
Member, High Resolution Electron Microscopy Facility (HREMF) Oversight Committee, The University of Texas MD Anderson Cancer Center, 2009 - Present
Honors & Awards
| 2026 | 2027 Faculty Achievement Award-Research Excellence - Translational, The University of Texas MD Anderson Cancer Center |
| 2016 | Hyundai Hope on Wheels Research Scholar Award, Hyundai |
| 2015 | Pediatric Clinical Innovator Award/Pediatric Multidisciplinary Award, The University of Texas MD Anderson Cancer Center |
| 2012 | Bio Houston Annual Luncheon Celebrating Women Invited to attend in Science, The University of Texas MD Anderson Cancer Center |
| 2012 | MD Anderson Women Faculty Accepted to Attend The 2012 AAMC Professional Development Seminars, The University of Texas MD Anderson Women Faculty |
| 2007 - 2008 | Mike Doiron Memorial 18th Annual Legends of Friendswood Education Foundation Award, The University of Texas M. D. Anderson Cancer Center and The Legends of Friendswood Education Foundation |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. Graduate Student Research Day- GSRD 2024. Poster. GSBS Student Research Day. Houston, Texas, US.
- 2022. AI in Healthcare: Future Applications of AI: What can AI do for you?. Conference. AI in Healthcare: Future Applications of AI: What can AI do for you?. Houston, TX, US.
- 2022. Mentoring Day 2022. Conference. Mentoring Day 2022. Houston, TX, US.
- 2021. New approaches to enhance adoptive transfer of NK cell therapy against Osteosarcoma. Conference. New approaches to enhance adoptive transfer of NK cell therapy against Osteosarcoma. Houston, TX, US.
- 2020. Research. Conference. Research. Houston, TX, US.
- 2020. Deciphering chemotherapy-induced autophagy in Osteosarcoma. Potential role of BRD4. Conference. Deciphering chemotherapy-induced autophagy in Osteosarcoma. Potential role of BRD4. Houston, TX, US.
- 2019. The IL-2 Cytokine. Potential Applications for the treatment of Osteosarcoma. Conference. The IL-2 Cytokine. Potential Applications for the treatment of Osteosarcoma. Houston, TX, US.
- 2019. The IL-2 Cytokine. Potential Applications for the treatment of Osteosarcoma. Conference. The IL-2 Cytokine. Potential Applications for the treatment of Osteosarcoma. Houston, TX, US.
- 2019. Unraveling the role of Autophagy in Osteosarcoma Therapeutic Implications. Conference. Unraveling the role of Autophagy in Osteosarcoma Therapeutic Implications. Houston, TX, US.
- 2019. Pediatric Sarcoma and Solid Tumor Team Update. Conference. Pediatric Sarcoma and Solid Tumor Team Update. Houston, TX, US.
- 2018. Pediatric Solid Tumor Comprehensive Date Resource Core - Energy Transfer Partners. Conference. Pediatric Solid Tumor Comprehensive Date Resource Core - Energy Transfer Partners. Houston, TX, US.
- 2018. Pediatric Solid Tumor Comprehensive Date Resource Core Team Update. Conference. Pediatric Solid Tumor Comprehensive Date Resource Core Team Update. Houston, TX, US.
- 2018. Pediatric Solid Tumor Comprehensive Data Resource Core. Conference. Pediatric Solid Tumor Comprehensive Data Resource Core. Houston, TX, US.
- 2018. Solid Tumors. Conference. Solid Tumors. Houston, TX, US.
- 2018. Osteosarcoma Challenges and Alternative Therapeutic Approaches. Conference. Osteosarcoma Challenges and Alternative Therapeutic Approaches. Houston, TX, US.
- 2018. A Doctor's career path. From Medical School to Faculty. Conference. A Doctor's career path. From Medical School to Faculty. Houston, TX, US.
- 2017. Aerosol Chemotherapy for Osteosarcoma Lung Metastases. Conference. Aerosol Chemotherapy for Osteosarcoma Lung Metastases. Houston, TX, US.
- 2017. Osteosarcoma: Alternative approaches to enhance therapeutic efficacy. Conference. Osteosarcoma: Alternative approaches to enhance therapeutic efficacy. Houston, TX, US.
- 2017. Pediatric Sarcoma and Solid Tumor Team Update. Conference. Pediatric Sarcoma and Solid Tumor Team Update. Houston, TX, US.
- 2016. The autophagy paradigm in Osteosarcoma. Conference. The autophagy paradigm in Osteosarcoma. Houston, TX, US.
- 2015. Aerosol delivery as a novel approach to treat Osteosarcoma lung metastases. "The better and the best". Conference. Aerosol delivery as a novel approach to treat Osteosarcoma lung metastases. "The better and the best". Houston, TX, US.
- 2014. Unraveling Autophagy in Osteosarcoma. Conference. Unraveling Autophagy in Osteosarcoma. Houston, TX, US.
- 2014. Modulating Autophagy as a new approach to enhance Chemotherapeutic Efficacy in Osteosarcoma. Conference. Modulating Autophagy as a new approach to enhance Chemotherapeutic Efficacy in Osteosarcoma. Houston, TX, US.
- 2014. Aerosol Interleukin-2 for the treatment of patients ≥12 years old with lung metastases from Osteosarcoma: A phase I trial. Conference. Aerosol Interleukin-2 for the treatment of patients ≥12 years old with lung metastases from Osteosarcoma: A phase I trial. Houston, TX, US.
- 2013. Chemotherapy. Conference. Chemotherapy. Houston, TX, US.
- 2012. Osteosarcoma, the microenvironment and autophagy as a proposed mechanism of tumor resistance to chemotherapy. Conference. Osteosarcoma, the microenvironment and autophagy as a proposed mechanism of tumor resistance to chemotherapy. Houston, TX, US.
- 2012. Getting organized and time management. Conference. Getting organized and time management. Houston, TX, US.
- 2011. Texas 4000 for Cancer Site Visit. Conference. Texas 4000 for Cancer Site Visit. Houston, TX, US.
- 2011. Tumor microenvironment as a key factor for chemotherapeutic efficacy. Conference. Tumor microenvironment as a key factor for chemotherapeutic efficacy. Houston, TX, US.
- 2010. Osteosarcoma. Conference. Osteosarcoma. Houston, TX, US.
- 2010. Aerosol chemotherapy for the treatment of Osteosarcoma lung metastases. Tumor microenvironment and the Fas/FasL apoptotic pathway. The story continues... Conference. Aerosol chemotherapy for the treatment of Osteosarcoma lung metastases. Tumor microenvironment and the Fas/FasL apoptotic pathway. The story continues... Houston, TX, US.
- 2010. Aerosol Gemcitabine for the treatment of Osteosarcoma lung metastases and implications of the Fas/FasL pathway. More to learn... Conference. Aerosol Gemcitabine for the treatment of Osteosarcoma lung metastases and implications of the Fas/FasL pathway. More to learn... Houston, TX, US.
- 2009. Tumor microenvironment contributes to the development of osteosarcoma lung metastases and influences therapeutic efficacy. Conference. Tumor microenvironment contributes to the development of osteosarcoma lung metastases and influences therapeutic efficacy. Houston, TX, US.
Regional Presentations
- 2023. Applying for a Teaching/Research Faculty Position. Conference. Applying for a Teaching/Research Faculty Position, US.
- 2022. Mentoring Works Workshop. Conference. Mentoring Works Workshop, US.
- 2021. Enhancing Treatment Response in Recurrent / Metastatic Osteosarcoma with Hydroxychloroquine (Finalist). Conference. Enhancing Treatment Response in Recurrent / Metastatic Osteosarcoma with Hydroxychloroquine (Finalist), US.
- 2020. Exercise as a novel approach to enhance NK cells therapeutic effect against Osteosarcoma. Conference. Exercise as a novel approach to enhance NK cells therapeutic effect against Osteosarcoma. Orlando, FL, US.
National Presentations
- 2024. COG Fall Meeting. Poster. New Orleans, Louisiana, US.
- 2024. Alternative treatment strategies for Osteosarcoma. Invited. Ellis Fischel Cancer Center Grand Rounds, MO, US.
- 2023. BRD4 Regulates Gemcitabine Efficacy by Modulating Autophagy Activity in Osteosarcoma Cells. Invited. Keystone Symposia Autophagy and Neurodegeneration. Snowbird, UT, US.
- 2022. BRD4 Regulates Gemcitabine Efficacy by Modulatig Autophagy Activity in Osteosarcoma Cells. Conference. BRD4 Regulates Gemcitabine Efficacy by Modulatig Autophagy Activity in Osteosarcoma Cells, US.
- 2022. TARGETING CD70 USING CAR-NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA. Conference. TARGETING CD70 USING CAR-NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA. San Diego, CA, US.
- 2022. Aerosolized Gemcitabine Modulates the Osteosarcoma Tumor Microenvironment and Increases Natural Killer Cell Efficacy. Conference. Aerosolized Gemcitabine Modulates the Osteosarcoma Tumor Microenvironment and Increases Natural Killer Cell Efficacy. San Diego, CA, US.
- 2022. Aerosolized Gemcitabine Modulates Osteosarcoma Tumor Microenvironment and Increases NK Cell Efficacy. Conference. Aerosolized Gemcitabine Modulates Osteosarcoma Tumor Microenvironment and Increases NK Cell Efficacy. Pittsburgh, PA, US.
- 2022. TARGETING CD70 USING CAR-NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA. Conference. TARGETING CD70 USING CAR-NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA. Pittsburgh, PA, US.
- 2021. Epigenetic Modulation of NK Cells to Improve Tumor Trafficking and Enhance Therapeutic Efficacy Against Osteosarcoma [Poster Presentation]. Conference. Epigenetic Modulation of NK Cells to Improve Tumor Trafficking and Enhance Therapeutic Efficacy Against Osteosarcoma [Poster Presentation], US.
- 2020. CD24-Specific CAR T cell therapy for Osteosarcoma. [Poster Presentation]. Conference. CD24-Specific CAR T cell therapy for Osteosarcoma. [Poster Presentation], US.
- 2020. A Phase I Trial of Aerosol Gemcitabine for the Treatment of Patients with Solid tumors and lung Metastases. [Poster Presentation]. Conference. A Phase I Trial of Aerosol Gemcitabine for the Treatment of Patients with Solid tumors and lung Metastases. [Poster Presentation], US.
- 2020. Exercise as a novel approach to enhance NK cell therapeutic against Osteosarcoma. Poster. Orlando, FL.
- 2019. Exosomal communication by metastatic osteosarcoma cells contributes to the modulation of macrophages to an M2 tumor-promoting phenotype [Poster Presentation]. Conference. Exosomal communication by metastatic osteosarcoma cells contributes to the modulation of macrophages to an M2 tumor-promoting phenotype [Poster Presentation]. San Diego, CA, US.
- 2019. A potential immunotherapeutic approach for the treatment of Osteosarcoma [Poster Presentation]. Conference. A potential immunotherapeutic approach for the treatment of Osteosarcoma [Poster Presentation]. Atlanta, GA, US.
- 2019. Phosphorylated HSP27 to predict the role of Gemcitabine induced autophagy in osteosarcoma [Poster Presentation]. Conference. Phosphorylated HSP27 to predict the role of Gemcitabine induced autophagy in osteosarcoma [Poster Presentation]. Santa Fe, NM, US.
- 2018. Autophagy and HSP27. A potential link to define autophagy fate in Osteosarcoma [Poster presentation]. Conference. Autophagy and HSP27. A potential link to define autophagy fate in Osteosarcoma [Poster presentation]. Boston, MA, US.
- 2016. HSP27 as a Potential Factor to Determine the Fate of Gemcitabine-Induced Autophagy in osteosarcoma: Survival vs. Death, Poster Presentation. Conference. HSP27 as a Potential Factor to Determine the Fate of Gemcitabine-Induced Autophagy in osteosarcoma: Survival vs. Death, Poster Presentation. Whistler.
- 2016. A combination approach targeting osteosarcoma cells in-vitro using IL-11Ra CAR T-cells with Anti-PD-1 Blockade. Conference. A combination approach targeting osteosarcoma cells in-vitro using IL-11Ra CAR T-cells with Anti-PD-1 Blockade. Minneapolis, MN, US.
- 2014. Autophagy as a mechanism of resistance implicated in Osteosarcoma response to Gemcitabine. Conference. Autophagy as a mechanism of resistance implicated in Osteosarcoma response to Gemcitabine. Chicago, IL, US.
- 2013. A feasibility and safety of aerosol IL-2 in patients with lung metastases for future combination therapies for the treatment of osteosarcoma lung metastases. Conference. A feasibility and safety of aerosol IL-2 in patients with lung metastases for future combination therapies for the treatment of osteosarcoma lung metastases. San Diego, CA, US.
- 2013. Clinical evaluation of aerosol IL-2 in patients with lung metastases to test feasibility and safety for future combination therapy using infused natural killer cell. Conference. Clinical evaluation of aerosol IL-2 in patients with lung metastases to test feasibility and safety for future combination therapy using infused natural killer cell. Boston, MA, US.
- 2013. The microenvironment plays an important role in the ability of aerosol Gemcitabine and Liposomal 9-Nitrocamptothecin to elicit therapeutic effect on Osteosarcoma lung metastases. Conference. The microenvironment plays an important role in the ability of aerosol Gemcitabine and Liposomal 9-Nitrocamptothecin to elicit therapeutic effect on Osteosarcoma lung metastases. Boston, MA, US.
- 2011. The microenvironment plays an important role in the ability of aerosol Gemcitabine and Liposomal 9-Nitrocamptothecin to elicit therapeutic effect on Osteosarcoma lung metastases. Conference. The microenvironment plays an important role in the ability of aerosol Gemcitabine and Liposomal 9-Nitrocamptothecin to elicit therapeutic effect on Osteosarcoma lung metastases. Orlando, FL, US.
- 2007. Fas Ligand is critical to the therapeutic efficacy of aerosol Gemcitabine against Osteosarcoma lung metastases. Conference. Fas Ligand is critical to the therapeutic efficacy of aerosol Gemcitabine against Osteosarcoma lung metastases. Los Angeles, CA, US.
- 2005. Fas expression in osteosarcoma lung metastasis is correlated with chemotherapy prior to surgery. Conference. Fas expression in osteosarcoma lung metastasis is correlated with chemotherapy prior to surgery. Anaheim, CA, US.
- 2004. Fas expression is critical to the metastatic potential of murine Osteosarcoma cell line and can be used as a therapeutic target. Conference. Fas expression is critical to the metastatic potential of murine Osteosarcoma cell line and can be used as a therapeutic target. Orlando, FL, US.
International Presentations
- 2026. Pramlintide Modulates Osteosarcoma Metabolism and Improves NK Cell Therapy. Poster. 2026 CTOS Annual Meeting, KR.
- 2026. HSP27-Mediated Mitophagy Regulation Enhances Osteosarcoma Cells Sensitivity To Gemcitabine. Poster. 2026 CTOS Annual Meeting. Seoul, KR.
- 2023. TARGETING CD70 USING CAR NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA. Poster. 2023 CTOS Annual Meeting, IE.
- 2023. EPIGENETIC MODULATION OF NK CELLS IMPROVES TUMOR TRAFFICKING AND ENHANCES THERAPEUTIC EFFICACY AGAINST OSTEOSARCOMA. Poster. 2023 CTOS Annual Meeting Acceptance, IE.
- 2019. Osteosarcoma. Challenges and Alternative Therapeutic Approaches. Invited. Osteosarcoma. Challenges and Alternative Therapeutic Approaches, US.
- 2019. Enumeration of cell surface vimentin positive cells as a method of detecting tumor cells in pediatric patients with sarcoma. Conference. Enumeration of cell surface vimentin positive cells as a method of detecting tumor cells in pediatric patients with sarcoma. Tokyo, JP.
- 2019. Enumeration of Cell Surface Vimentin Positive Cells as a Method for Detecting Circulating Tumor Cells in Pediatric Patients with Sarcoma. Conference. Enumeration of Cell Surface Vimentin Positive Cells as a Method for Detecting Circulating Tumor Cells in Pediatric Patients with Sarcoma, JP.
- 2016. Targeting the PD-1/PDL-1 Signaling Pathway for the Treatment of Osteosarcoma Lung Metastasis. Conference. Targeting the PD-1/PDL-1 Signaling Pathway for the Treatment of Osteosarcoma Lung Metastasis. Lisbon, PT.
Grant & Contract Support
| Date: | 2027 - 2032 |
| Title: | Gemcitabine Prodrugs for the Treatment of Osteosarcoma Lung Metastases |
| Funding Source: | Virginia Commonwealth University |
| Role: | Co-I |
| ID: | FP00027385 |
| Date: | 2027 - 2032 |
| Title: | Targeting Tumor Microenvironment Metabolic Alterations to Enhance Immunotherapy Efficacy in Osteosarcoma |
| Funding Source: | NIH |
| Role: | PI |
| ID: | CA307048 |
| Date: | 2027 - 2028 |
| Title: | A Novel Dual-Target Therapeutic Strategy for Relapsed/Recurrent Osteosarcoma: Combining Cagrilintide with CD70-Directed Chimeric antigen receptor (CAR) Natural Killer (NK) Cells to overcome therapeutic resistance |
| Funding Source: | Golfers Against Cancer |
| Role: | PI |
| Date: | 2027 - 2027 |
| Title: | Restoring Immune Competence in osteosarcoma Lung metastases |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2027 - 2027 |
| Title: | A new approach to metabolic modulation of the osteosarcoma lung tumor microenvironment |
| Funding Source: | Elsa U. Pardee Foundation |
| Role: | PI |
| Date: | 2026 - 2031 |
| Title: | Orally Inhaled Combination Therapies for the Treatment of Osteosarcoma Lung Metastases |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Co-I |
| Date: | 2026 - 2030 |
| Title: | Enhancing Immunotherapy in Osteosarcoma Through Tumor Microenvironment Metabolic Modulation |
| Funding Source: | Cancer Prevention Research Institute of Texas |
| Role: | PI |
| ID: | RP270520 |
| Date: | 2026 - 2027 |
| Title: | Amylin Analogs and NK cell Therapy to treat Osteosarcoma Lung Metastases- Pediatrics Imaging Team |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2026 - 2027 |
| Title: | Exercise suppression of glycolysis may enhance the response of Ewing sarcoma lung metastases to existing therapies |
| Funding Source: | Charlie Landers Foundation |
| Role: | Co-I |
| Date: | 2026 - Present |
| Title: | Lung-Targeted Metabolic Modulation as a Strategy to Enhance Immunotherapy for Metastatic Ewing Sarcoma |
| Funding Source: | Charlie Landers Foundation’s |
| Role: | PI |
| Date: | 2025 - 2030 |
| Title: | Targeting Tumor Microenvironment Metabolic Alterations to Enhance Immunotherapy Efficacy in Osteosarcoma |
| Funding Source: | NIH |
| Role: | PI |
| Date: | 2025 - 2029 |
| Title: | HyperCEST Imaging of Cellular Immunotherapy for Treatment of Metastatic Osteosarcoma |
| Funding Source: | Cancer Prevention Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| Date: | 2025 - 2026 |
| Title: | Molecular Imaging of Tumor Metabolism and Perfusion to guide Immunotherapy in Ewing Sarcoma |
| Funding Source: | Elsa U Pardee Foundation |
| Role: | PI |
| Date: | 2025 - 2027 |
| Title: | 129Xe Hyperpolarized Chemical Exchange Saturation Transfer (HyperCEST) MRI for Tracking Immunotherapy Delivery in the Lungs |
| Funding Source: | NIH/NCI |
| Role: | Other Significant Contributor |
| ID: | 1F31CA305956-01 |
| Date: | 2025 - 2027 |
| Title: | Metabolic and perfusion changes in Ewing Sarcoma after treatment |
| Funding Source: | A Collaborative Pediatric Cancer Research Awards Program |
| Role: | PI |
| Date: | 2025 - 2026 |
| Title: | Imaging tools to address metabolic changes and immune therapy response in Osteosarcoma |
| Funding Source: | MIB Agents |
| Role: | PI |
| Date: | 2025 - 2026 |
| Title: | Imaging Metabolic Shifts in Ewing Sarcoma Post-Therapy and its Impact on Immune Therapy Efficacy |
| Funding Source: | Charlie Landers Foundation |
| Role: | PI |
| Date: | 2025 - 2030 |
| Title: | Childhood and Adolescent/ Young Adult Cancer research Resource (CARE) |
| Funding Source: | CPRIT |
| Role: | Key |
| ID: | RP250546 |
| Date: | 2025 - 2026 |
| Title: | A Metabolic approach to improve cDCVs-mediated increased immune anti-tumor response in Osteosarcoma |
| Funding Source: | Elsa U Pardee Foundation |
| Role: | PI |
| Date: | 2025 - 2026 |
| Title: | Targeting metabolic adaptations to boost immunotherapy effectiveness in Osteosarcoma |
| Funding Source: | Louis B. Mayer |
| Role: | PI |
| Date: | 2025 - 2026 |
| Title: | Metabolic reprogramming of the Tumor Microenvironment to enhance NK cell therapy against Osteosarcoma |
| Funding Source: | TAMEST – 2025 Hill Prizes |
| Role: | Co-PI |
| Date: | 2025 - Present |
| Title: | Redefining the Osteosarcoma Lung Metastatic Microenvironment |
| Funding Source: | MIB Agents |
| Role: | PI |
| Date: | 2024 - 2029 |
| Title: | New approach for osteosarcoma: Enhancing and monitoring NK cell therapy |
| Funding Source: | NIH |
| Role: | PI |
| ID: | P01CA275719 |
| Date: | 2024 - 2026 |
| Title: | Metabolic Reprograming of the Ewing Sarcoma Tumor Microenvironment using Pramlintide to augment NK cell immunotherapy |
| Funding Source: | St. Baldrick |
| Role: | PI |
| Date: | 2024 - 2025 |
| Title: | Anti-PD1 and NK cells for the treatment of Osteosarcoma |
| Funding Source: | MIB |
| Role: | PI |
| Date: | 2024 - 2025 |
| Title: | Metabolic Reprogramming of the Ewing Sarcoma Tumor Microenvironment using Pramlintide to Augment NK cell Immunotherapy |
| Funding Source: | Charlie Landers Foundation |
| Role: | PI |
| Date: | 2024 - 2026 |
| Title: | Metabolic Reprograming of the Ewing Sarcoma Tumor Microenvironment using Pramlintide to augment NK cell immunotherapy |
| Funding Source: | CURE Childhood Cancer |
| Role: | PI |
| Date: | 2024 - 2026 |
| Title: | Exercise to Enhance NK Cell Therapy for Osteosarcoma |
| Funding Source: | 2023-2024 Grants to Enhance and Advance Research Program |
| Role: | Co-I |
| Date: | 2024 - Present |
| Title: | Novel approach to NK cell therapy for recurrent/refractory pediatric medulloblastoma |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | FP00021983 |
| Date: | 2024 - Present |
| Title: | Metabolic Reprograming of the Ewing Sarcoma Tumor Microenvironment using Pramlintide to augment NK cell |
| Funding Source: | CCCF - CURE Childhood Cancer Translation to CURE Award (T2C) |
| Role: | Co-PI |
| ID: | 1294336 |
| Date: | 2024 - Present |
| Title: | MD Anderson Advancing Research Careers (ARC) UE5, Bridge Coach |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Co-I |
| Date: | 2024 - 2024 |
| Title: | Metabolic reprogramming of the tumor microenvironment to enhance NK cell therapy against Osteosarcoma |
| Funding Source: | Elsa U Pardee |
| Role: | PI |
| Date: | 2023 - 2025 |
| Title: | Metabolic reprogramming of the Tumor Microenvironment to enhance NK cell therapy against Osteosarcoma |
| Funding Source: | Osteosarcoma Institute |
| Role: | PI |
| Date: | 2023 - 2025 |
| Title: | Metabolic reprogramming of the Tumor Microenvironment to enhance NK cell therapy against Osteosarcoma |
| Funding Source: | IRG |
| Role: | PI |
| Date: | 2023 - 2025 |
| Title: | Hyperpolarized 129Xe MRI for imaging NK cell therapy of lung metastasis |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| ID: | R21 |
| Date: | 2022 - 2025 |
| Title: | Phase I study of aerosol Gemcitabine for patients with solid tumors and lung metastases |
| Funding Source: | Gateway for Cancer Research |
| Role: | PI |
| Date: | 2022 - 2024 |
| Title: | Imaging habitats of response to NK cell immunotherapy in Osteosarcoma |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| Date: | 2022 - 2024 |
| Title: | Defining the role of BRD4 and G9a in chemotherapy-induced autophagy in Osteosarcoma |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2022 - 2024 |
| Title: | Exercise as a novel approach to enhance NK cells therapeutic effect against Osteosarcoma |
| Funding Source: | Children’s Cancer Research Fund-Hard to treat award |
| Role: | PI |
| Date: | 2021 - 2023 |
| Title: | Infrastructure establishment for longitudinal collection of pediatric biospecimens for integrated molecular characterization |
| Funding Source: | John S. Dunn Foundation |
| Role: | Co-PI |
| Date: | 2021 - 2023 |
| Title: | A novel epigenetic mechanism to define chemotherapy-induced autophagy outcome in Osteosarcoma |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2021 - 2024 |
| Title: | Repurposing Hydroxychloroquine to inhibit Autophagy in Patients with Recurrent/Metastatic Osteosarcoma to Enhance Treatment Response –to support the Biopsies and correlative studies |
| Funding Source: | The Cure Accelerator/Cure |
| Role: | PI |
| Date: | 2021 - 2023 |
| Title: | Aerosol Gemcitabine to enhance Natural Killer cell therapy against Osteosarcoma Lung metastases |
| Funding Source: | Cure accelerator/Cure within reach |
| Role: | PI |
| Date: | 2021 - 2023 |
| Title: | Exercise as a novel approach to enhance NK cells therapeutic effect against Osteosarcoma |
| Funding Source: | Chance for Life |
| Role: | PI |
| Date: | 2021 - 2022 |
| Title: | Exercise as a novel approach to enhance NK cells therapeutic effect against Osteosarcoma |
| Funding Source: | IRG |
| Role: | PI |
| Date: | 2020 - 2021 |
| Title: | Administrative Supplements for the NCI P30 Cancer Center Support Grants to develop the National Childhood Cancer Registry |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| Date: | 2020 - 2020 |
| Title: | Immunotherapy approach for the treatment of Osteosarcoma |
| Funding Source: | Curing Kids Cancer Foundation |
| Role: | PI |
| Date: | 2019 - 2022 |
| Title: | (Project I), NK Cell Therapy for Refractory or Relapsed Osteosarcoma |
| Funding Source: | Multidisciplinary Research Program (MRP) |
| Role: | PI |
| Date: | 2019 - 2020 |
| Title: | 19F MRI as an imaging tool to evaluate adoptive transfer of NK cells in Osteosarcoma |
| Funding Source: | The University of Texas M.D. Anderson Cancer Center (The Center for Advanced Biomedical Imaging) |
| Role: | Co-PI |
| ID: | CABI Pilot Project Program (“CP3”) |
| Date: | 2018 - 2024 |
| Title: | Pediatric Solid Tumors Comprehensive Data Resource Core |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | CO-I |
| Date: | 2017 - 2021 |
| Title: | Immunotherapy for sarcomas |
| Funding Source: | Philanthropic Funds |
| Role: | PI |
| Date: | 2017 - 2021 |
| Title: | Houston Tri Delta Organization |
| Funding Source: | Philanthropic Funds |
| Role: | PI |
| Date: | 2017 - 2022 |
| Title: | Identification of a predictive biomarker to define the role of Chemotherapy-induced autophagy in Osteosarcoma |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2016 - 2022 |
| Title: | Phase I study of aerosol Gemcitabine for patients with solid tumors and lung metastases |
| Funding Source: | Gateway for Cancer Research |
| Role: | PI |
| Date: | 2016 - 2019 |
| Title: | Autophagy and heat shock protein 27 in osteosarcoma response to chemotherapy |
| Funding Source: | Hyundai Hope on Wheels |
| Role: | PI |
| Date: | 2016 - 2020 |
| Title: | The Autophagy paradox in Osteosarcoma and the role of heat shock protein 27 |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| Date: | 2016 - 2018 |
| Title: | Phase I study of Aerosol Gemcitabine for sarcoma lung metastases and Heat shock protein 27 as a potential biomarker to predict the role of autophagy on drug sensitivity |
| Funding Source: | Pediatric Multidisciplinary Clinical Award - The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2016 - 2021 |
| Title: | Phase I Study of Aerosol Gemcitabine for Pulmonary metastases |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2016 - 2017 |
| Title: | Autophagy role in Osteosarcoma response to aerosol chemotherapy |
| Funding Source: | St. Baldrick's Foundation |
| Role: | PI |
| Date: | 2016 - 2018 |
| Title: | Strategic Alliance: Effect of NKTR-214 treatment alone vs combination NKTR-214+Anti-PD1 in Osteosarcoma primary tumor and pulmonary metastasis |
| Funding Source: | Nektar Therapeutics |
| Role: | PI |
| Date: | 2016 - 2017 |
| Title: | Predicting drug-induced autophagy response in Osteosarcoma |
| Funding Source: | Sarcoma Foundation of America |
| Role: | PI |
| Date: | 2016 - 2020 |
| Title: | Heat Shock protein 27 as a biomarker predicting the role of chemotherapy-induced autophagy on drug Sensitivity |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| Date: | 2016 - 2017 |
| Title: | Repurposed Gemcitabine by using aerosol delivery to Treat lung metastases |
| Funding Source: | Cure Accelerator |
| Role: | PI |
| Date: | 2016 - 2017 |
| Title: | Phase I study of Aerosol Gemcitabine for the treatment of solid tumors and lung metastases |
| Funding Source: | United-4 A Cure Cancer |
| Role: | PI |
| Date: | 2016 - 2016 |
| Title: | Phase I study of Aerosol Gemcitabine for sarcoma lung metastases and Heat shock protein 27as a potential biomarker to predict the role of autophagy on drug sensitivity |
| Funding Source: | Wipe Out Kids Cancer |
| Role: | PI |
| Date: | 2015 - 2016 |
| Title: | Aerosol Gemcitabine-induced autophagy in Osteosarcoma lung metastasis |
| Funding Source: | St. Baldrick's Foundation |
| Role: | PI |
| Date: | 2015 - 2016 |
| Title: | Targeting autophagy to improve aerosol chemotherapy effect in Osteosarcoma |
| Funding Source: | Sarcoma Foundation of America |
| Role: | PI |
| Date: | 2014 - 2019 |
| Title: | Phase I/II Study of Aerosol Interleukin-2 for Pulmonary Metastases |
| Funding Source: | NIH/NCI |
| Role: | Multi-PI |
| ID: | 1R01 CA187181-01 |
| Date: | 2014 - 2017 |
| Title: | Interplay between autophagy and phosphorylated heat shock protein 27 in Osteosarcoma following aerosol Gemcitabine |
| Funding Source: | TJ Martell Foundation |
| Role: | PI |
| Date: | 2014 - 2021 |
| Title: | Aerosol Therapy Trial for relapsed Sarcoma Lung Metastases |
| Funding Source: | Philanthropic Funds |
| Role: | PI |
| Date: | 2014 - 2016 |
| Title: | Phase II study of aerosol Interleukin-2 for Osteosarcoma pulmonary metastases |
| Funding Source: | The Gateway for Cancer Research Foundation |
| Role: | Co-PI |
| Date: | 2013 - 2015 |
| Title: | Combination therapy of aerosol Gemcitabine with a pharmacological inhibitor of autophagy to improve Gemcitabine therapeutic effect against Osteosarcoma metastatic disease |
| Funding Source: | AACR-Aflac Career Development Award |
| Role: | PI |
| Date: | 2012 - 2014 |
| Title: | Combination therapy of aerosol Gemcitabine with a pharmacological inhibitor of autophagy to improve Gemcitabine therapeutic effect against Osteosarcoma metastatic disease |
| Funding Source: | CureSearch Young Investigator Award in Bone Tumors |
| Role: | PI |
| Date: | 2012 - 2017 |
| Title: | Aerosol IL-2 Feasibility in OS patients 12-18 years and for lung NK cell expansion |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1R01CA166725-01 |
| Title: | Metabolic reprogramming of the tumor microenvironment to enhance NK cell therapy against Osteosarcoma |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA289241-01 |
| Title: | Phase I study of Aerosol Gemcitabine in Patients with Solid tumors and Pulmonary Metastases |
| Funding Source: | The University of Texas MD Anderson Cancer Center, High Impact |
| Role: | Co-PI |
| ID: | Clinical Research Support Grant (HI-CRSP) |
| Title: | Autophagy inhibition to enhance chemotherapy sensitivity |
| Funding Source: | MIB Agents Osteosarcoma Alliance |
| Role: | Co-PI |
| Title: | Phase I/II Study of Aerosol Interleukin-2 for Pulmonary Metastases |
| Funding Source: | UTMDACC Institutional Research Grant |
| Role: | Co-PI |
| Title: | Efficacy of Immunotherapy combination for the treatment of Osteosarcoma |
| Funding Source: | Cure Kids Cancer |
| Role: | PI |
| Title: | Reprogramming the Osteosarcoma Tumor Microenvironment to enhance Natural Killer cell therapy |
| Funding Source: | Men of Distinction |
| Role: | PI |
| Title: | Autophagy Inhibition in Patients with Recurrent/Metastatic Osteosarcoma to Enhance Response |
| Funding Source: | V Foundation |
| Role: | Co-PI |
Selected Publications
Peer-Reviewed Articles
- Offer K, Moody K, Andersen C, Wang J, Gordon NB. MISTOSUS: A Phase II trial of Viscum Album Extract Adjuvant Therapy for Relapsed Resectable Osteosarcoma. Future Oncology. e-Pub 2026. PMID: 41789811.
- Kang D, Courneya KS, Swartz MC, Vareki SM, Gordon NB, Rosa Neto JC, Schadler KL, Simpson RJ, Baker K, LaVoy EC. Exercise training intensity, immune cells, and cancer outcomes: A scoping review. JNCI Cancer Spectrum, 2026. e-Pub 2026. PMID: 41795834.
- LaVoy E, Dong-Woo K, Courneya K, Swartz MC, Maleki Vareki S, Gordon NB, Neto J, Simpson R, Scott Baker K, Schadler K. Chronic exercise training intensity, immune cells, and cancer outcomes: A scoping review. JNCI Cancer Spectrum. e-Pub 2026.
- Walker, D, Hall, A, Bonwell, A, Gordon, N, Robinson, D, Hollomon, M. FOXO1 Inhibition and FADD Knockdown Have Opposing Effects on Anticancer Drug-Induced Cytotoxicity and p21 Expression in Osteosarcoma Cells. International journal of molecular sciences 27(2), 2026. e-Pub 2026. PMID: 41596582.
- Jin, Y, Jia, Z, Xia, X, Gordon, N, Ludwig, JA, Somaiah, N, Li, S. Anti-CD137 agonist antibody–independent and clinically feasible preparation of tumor-infiltrating lymphocytes from soft tissue sarcoma and osteosarcoma. Frontiers in immunology 16, 2025. e-Pub 2025. PMID: 40145091.
- Sehl O, Yang Y, Anjier AR, Nevozhay D, Cheng D, Guo K, Fellows B, Mohtasebzadeh AR, Mason EE, Sanders T, Kim P, Trease D, Koul D, Goodwill PW, Sokolov K, Wintermark M, Gordon N, Greve JM, Gopalakrishnan V. Preclinical and Clinical-Scale Magnetic Particle Imaging of Natural Killer Cells: in vitro and ex vivo Demonstration of Cellular Sensitivity, Resolution, and Quantification. Mol Imaging Biol 27(1):78-88, 2024. e-Pub 2024. PMID: 39653984.
- Singh, A, Cheng, D, Swaminathan, J, Yang, Y, Zheng, Y, Gordon, N, Gopalakrishnan, V. REST-dependent downregulation of von Hippel-Lindau tumor suppressor promotes autophagy in SHH-medulloblastoma. Scientific reports 14(1), 2024. e-Pub 2024. PMID: 38866867.
- Livingston JA, Gill J, Conley AP, Somaiah N, Araujo D, Ratan R, Ravi V, Zarzour MA, Benjamin RS, Patel S, Daw N, Harrison D, Gorlick R, Otto T, Lin H, Wang W, Amini B, Kleinerman E, Gordon N. 1756P A phase I/II trial of gemcitabine, docetaxel, and hydroxychloroquine in advanced/metastatic osteosarcoma. Annals of Oncology 35(Supplement 2):S1046, 2024.
- Truong, D, Weistuch, C, Murgas, KA, Admane, P, King, BL, Chauviere Lee, J, Lamhamedi Cherradi, SE, Swaminathan, J, Daw Bitar, N, Gordon, N, Gopalakrishnan, V, Gorlick, R, Somaiah, N, Deasy, JO, Mikos, AG, Tannenbaum, A, Ludwig, JA. Mapping the Single-Cell Differentiation Landscape of Osteosarcoma. Clinical Cancer Research 30(15):3259-3272, 2024. e-Pub 2024. PMID: 38775859.
- Truong, DD, Lamhamedi-Cherradi, SE, Porter, RW, Krishnan, S, Swaminathan, J, Gibson, A, Lazar, A, Livingston, JA, Gopalakrishnan, V, Gordon, N, Daw Bitar, N, Navin, N, Gorlick, R, Ludwig, JA. Dissociation protocols used for sarcoma tissues bias the transcriptome observed in single-cell and single-nucleus RNA sequencing. BMC cancer 23(1), 2023. e-Pub 2023. PMID: 37254069.
- Rav, ES, Maegawa, S, Gopalakrishnan, V, Gordon, N. Overview of CD70 as a Potential Therapeutic Target for Osteosarcoma. Journal of Immunology 211(7):1067-1072, 2023. e-Pub 2023. PMID: 37722095.
- Cheng, D, Singh, A, Haltom, A, Zheng, Y, Sharma, A, Lopez, M, Gordon, N, Nancy, Gopalakrisnan, V, Vidya. MDB-33. REST AND USP37 Control The MTORC1-Autophagy Axis In Medulloblastoma By Regulating Raptor Degradation. Neuro-Oncology 25(Supplement_1):i69, 2023. e-Pub 2023.
- Truong DD, Lamhamedi-Cherradi SE, Porter RW, Krishnan S, Swaminathan J, Gibson AL, Lazar AJ, Livingston JA, Gopalakrishnan V, Gordon N, Daw NC, Gorlick R, Ludwig JA. Dissociation protocols used for sarcoma tissues bias the transcriptome observed in single-cell and single nucleus RNA sequencing. BioRxiv. e-Pub 2022. PMID: 37254069.
- Dao, L, Ragoonanan, D, Batth, IS, Satelli, A, Foglesong, JS, Wang, J, Zaky, W, Gill, JB, Liu, D, Albert, A, Gordon, N, Huh, W, Harrison, DJ, Herzog, CE, Kleinerman, ES, Gorlick, R, Daw Bitar, N, Li, S. Prognostic Value of Cell-Surface Vimentin-Positive CTCs in Pediatric Sarcomas. Frontiers in Oncology 11, 2021. e-Pub 2021. PMID: 34956881.
- Shi Y, Shen HM, Gopalakrishnan V, Gordon N. Epigenetic regulation of autophagy beyond the cytoplasm: a review. Front Cell Dev Biol 9:675599, 2021. e-Pub 2021. PMID: 34195194.
- Hennessy M, Wahba A, Felix K, Cabrera M, Segura MG, Kundra V, K Ravoori M, Stewart J, Kleinerman ES, Jensen V, Gopalakrishnan V, Pena R, Quach P, Kim G, Kivimäe S, Madakamutil L, Overwijk WW, Zalevsky J, Gordon N. Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma. Int J Cancer 148(8):1928-1937, 2020. e-Pub 2020. PMID: 33152115.
- Wolf-Dennen K, Gordon N, Kleinerman ES. Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions. Oncoimmunology 9(1):1747677, 2020. e-Pub 2020. PMID: 32313728.
- Hollomon MG, Patterson L, Santiago-O'Farrill J, Kleinerman ES, Gordon N. Knock down of Fas-Associated Protein with Death Domain (FADD) Sensitizes Osteosarcoma to TNFα-induced Cell Death. J Cancer 11(7):1657-1667, 2020. e-Pub 2020. PMID: 32194778.
- Kennis BA, Michel KA, Brugmann WB, Laureano A, Tao RH, Somanchi SS, Einstein SA, Bravo-Alegria JB, Maegawa S, Wahba A, Kiany S, Gordon N, Silla L, Schellingerhout D, Khatua S, Zaky W, Sandberg D, Cooper L, Lee DA, Bankson JA, Gopalakrishnan V. Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. J Neurooncol 142(3):395-407, 2019. e-Pub 2019. PMID: 30788681.
- Santiago-O'Farrill JM, Kleinerman ES, Hollomon MG, Livingston A, Wang WL, Tsai JW, Gordon NB. Phosphorylated heat shock protein 27 as a potential biomarker to predict the role of chemotherapy-induced autophagy in osteosarcoma response to therapy. Oncotarget 9(2):1602-1616, 2018. e-Pub 2018. PMID: 29416717.
- Kleinerman, ES, Yu, L, Dao, JQ, Hayes-Jordan, A, Lindsey, B, Kawedia, J, Stewart, J, Gordon, N. Aerosol Gemcitabine after Amputation Inhibits Osteosarcoma Lung Metastases but Not Wound Healing. Sarcoma 2018, 2018. e-Pub 2018. PMID: 29610563.
- Dhupkar P, Gordon N, Stewart J, Kleinerman ES. Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. Cancer Med 7(6):2654-2664, 2018. e-Pub 2018. PMID: 29733528.
- Livingston JA, Wang WL, Tsai JW, Lazar AJ, Leung CH, Lin H, Advani S, Daw N, Santiago-O'Farrill J, Hollomon M, Gordon NB, Kleinerman ES. Analysis of HSP27 and the autophagy marker LC3B+ puncta following preoperative chemotherapy identifies high-risk osteosarcoma patients. Mol Cancer Ther 17(6):1315-1323, 2018. e-Pub 2018. PMID: 29592877.
- Moonat HR, Huang G, Dhupkar P, Schadler K, Gordon N, Kleinerman ES. Combination of Interleukin-11Ra Chimeric Antigen Receptor T-cells and Programmed Death-1 Blockade as an Approach to Targeting Osteosarcoma Cells In vitro. Cancer Translational Medicine 3(4):139-45, 2017. e-Pub 2017.
- Guma SR, Lee DA, Ling Y, Gordon N, Kleinerman ES. Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis. Pediatr Blood Cancer 61(8):1362-8, 2014. e-Pub 2014. PMID: 24610870.
- Guma SR, Lee DA, Yu L, Gordon N, Hughes D, Stewart J, Wang WL, Kleinerman ES. Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis. Pediatr Blood Cancer 61(4):618-26, 2014. e-Pub 2014. PMID: 24136885.
- Hollomon MG, Gordon N, Santiago-O'Farrill JM, Kleinerman ES. Knockdown of autophagy-related protein 5, ATG5, decreases oxidative stress and has an opposing effect on camptothecin-induced cytotoxicity in osteosarcoma cells. BMC Cancer 13(1):500, 2013. e-Pub 2013. PMID: 24160177.
- Rodriguez CO, Crabbs TA, Wilson DW, Cannan VA, Skorupski KA, Gordon N, Koshkina N, Kleinerman E, Anderson PM. Aerosol Gemcitabine: Preclinical Safety and In Vivo Antitumor Activity in Osteosarcoma-Bearing Dogs. J Aerosol Med Pulm Drug Deliv 23(4):197-206, 2010. e-Pub 2010. PMID: 19803732.
- Gordon N, Kleinerman ES. Aerosol Therapy for the Treatment of Osteosarcoma Lung Metastases: Targeting the Fas/FasL Pathway and Rationale for the use of Gemcitabine. J Aerosol Med Pulm Drug Deliv 23(4):189-96, 2010. e-Pub 2010. PMID: 20528149.
- Gordon N, Koshkina NV, Jia SF, Khanna C, Mendoza A, Worth LL, Kleinerman ES. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res 13(15 Pt 1):4503-10, 2007. e-Pub 2007. PMID: 17671136.
- Hahn KM, Johnson PH, Gordon N, Kuerer H, Middleton L, Ramirez M, Yang W, Perkins G, Hortobagyi GN, Theriault RL. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 107(6):1219-26, 2006. e-Pub 2006. PMID: 16894524.
- Gordon N, Arndt CA, Hawkins DS, Doherty DK, Inwards CY, Munsell MF, Stewart J, Koshkina NV, Kleinerman ES. Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 27(11):611-5, 2005. e-Pub 2005. PMID: 16282894.
- Gordon N, Mullen CA, Tran H, Worth L, Gomez Almaguer D, Chan KW. Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome. J Pediatr Hematol Oncol 25(10):824-6, 2003. e-Pub 2003. PMID: 14528111.
Invited Articles
- Bryce Beverlin II, Hindle M, P Worth Longest P, Ferguson M, Kuehl PJ, Lopez A, Montoya D, Gordon N, Anijer, A. Targeting Lung Tumors using a Novel Inhaled Excipient Enhanced Growth Gemcitabine Dry Powder Formulation. Quench Medical RDD:1-11, 2022. e-Pub 2022.
- O'Farrill JS, Gordon N. Autophagy in osteosarcoma. Adv Exp Med Biol 804:147-160, 2014. e-Pub 2014. PMID: 24924173.
- Gordon N, Kleinerman ES. The Role of Fas/FasL in the Metastatic Potential of Osteosarcoma and Targeting this Pathway for the Treatment of Osteosarcoma Lung Metastases. Cancer Treat Res 152:497-508, 2010. e-Pub 2010. PMID: 20213411.
Professional Educational Materials
- Gordon, Nancy B. Immunotherapy Research in Osteosarcoma. onclive.com, Live interview, 2017.
Abstracts
- Anjier A, Gordon NB. The anti-diabetic drug Pramlintide modulates osteosarcoma tumor metabolism and improves NK cell therapy. AACR Special Conference in Cancer Research: Breaking Barriers in the Fight Against Rare Cancers. e-Pub 2026.
- Woo Kang D, LaVoy Emily, Courneya K, Simpson RJ, Malekivareki S, Baker KS, Rosaneto J, Gordon NB, Seo I, Swartz MC. Exercise intensity in modulating immune responses and clinical outcomes in cancer survivors: A scoping review. ISEO Conference. e-Pub 2026.
- Zheng Yan, Gordon NB. Hsp27 Mediates Sensitivity to Gemcitabine through Mitophagy Regulation in Osteosarcoma. AACR Special Conference in Cancer Research: Breaking Barriers in the Fight Against Rare Cancers. e-Pub 2026.
- Gutierrez A, Ramakrishnan R, Rav E, Shrestha P, Anijer A, Zheng Y, Basar R, Acharya S, Rezvani K, Kleinerman E, Gordon N. Targeting CD70 for CAR NK Cell-Based Immunotherapy in Osteosarcoma. MPS World Summit, 2026. e-Pub 2026.
- Gutierrez A, Shrestha P, Anijer A, Zheng Y, Bazar R, Acharya S, Rezvani K, Kleinerman E, Gordon N. CD 70-directed CAR NK Cell Therapy in Osteosarcoma: Cytotoxic efficacy and Emerging Links to IL-17 Pathways. UT McGovern Fifthtenth Annual Pediatrics Fellows Research Symposium. e-Pub 2026.
- Ramakrishnan R, Gordon NB, Anjier A, Acharya S, Rezvani K, Zheng Y, Bitar D N, Gopalakrishnan v, Hollomon M, Kleinerman ES. IDENTIFYING POTENTIAL MECHANISM OF CYTOTOXICITY MEDIATED BY CD70 CAR NK CELLS AGAINST OSTEOSARCOMA. ASPHO. e-Pub 2025.
- Ramakrishnan R, Gordon NB. Identifying the potential mechanism of cytotoxicity mediated by CD70 directed Chimeric Antigen Receptor Natural Killer (CAR NK) cells against osteosarcoma. e-Pub 2025.
- Kleinerman, ES, Gordon NB, Watowich, S. A Novel Dendritic Cell Vaccine Targeting CD70 For Osteosarcoma Lung Metastases. SIOP, 2023. e-Pub 2023.
- Gordon, Nancy. Targeting CD70 using CAR NK cells to enhance NK cells cytolytic effect against osteosarcoma. CPRIT, 2023. e-Pub 2023.
- Rav ES, Gordon, N, Anjier A, Acharya S, Basar R, Wang Y, Daw N, Rezvani K, Gopalakrishnan V, Gorlick R, Kleinerman ES. Targeting CD70 using CAR NK cells to enhance NK cells cytolytic effect against osteosarcoma. CPRIT, 2023. e-Pub 2023.
- Rav, E, Anjier, A, Acharya, S, Basar, R, Wang, Y, Katy, R, Rezvani, Golakrishnan, Vidya, Gorlick, Richard, Kleinerman, Gordon EA, Nancy. Targeting CD70 using CAR NK cells to enhance NK cells cytolytic effect against osteosarcoma. IMMUNOLOGY2023, 2023. e-Pub 2023.
- Anjier, A, Gordon, N, Kingsley, C, Martinez, G, Bankson, J, Jim, Kundra, Vikas, Gopalakrishnan, Vidya, Kleinerman A, Eugenie. Low-dose aerosolized Gemcitabine modulates the Tumor Microenvironment and increases Natural Killer cell efficacy against Osteosarcoma Lung Metastasis. Resistant TME Keystone, 2023. e-Pub 2023.
- Anjier, Ariana, Gordon, Nancy, Kingsley, Charles, Martinez, Gary, Bankson, Jim, Kundra, Vikas, Gopalakrishnan, Vidya, Kleinerman E. Low-dose aerosolized Gemcitabine modulates the Tumor Microenvironment and increases Natural Killer cell efficacy against Osteosarcoma Lung Metastasis. Resistant TME Keystone, 2023. e-Pub 2023.
- Rav, Emily, Anjier, Ariana, Acharya, Sunil, Basar, Rafet, Wang, Yifei, Katy, Rezvani, Golakrishnan, Vidya, Gorlick, Richard, Kleinerman, Eugenie, Gordon, Nancy. Targeting CD70 using CAR NK cells to enhance NK cells cytolytic effect against osteosarcoma. IMMUNOLOGY2023, 2023. e-Pub 2023.
- Anjier, A, Maegawa, S, Gopalakrishnan, V, Bournat, J, Cheng, D, Yang, Y, Yanwen, Kingsley, Charles, Kulp, Adam, Kleinerman, Eugenie, Gordon A, Nancy. Epigenetic modulation of NK cells to improve tumor trafficking and enhance therapeutic efficacy against osteosarcoma. AACR Annual Meeting 2023, 2023. e-Pub 2023.
- Anjier, A, Shrestha, P, Maegawa, S, Gopalakrishnan, V, Bournat, J, Cheng, D, Yang, Y, Kingsley, C, Kulp, A, Meyer, J, Martinez, G, Bankson, J, Kleinerman, ES, Gordon A, N. Epigenetic modulation of NK cells improved tumor trafficking and enhances therapeutic efficacy against osteosarcoma. AACR Annual Meeting, 2023. e-Pub 2023.
- Anjier, Ariana, Maegawa, Shinji, Gopalakrishnan, Vidya, Bournat, Juan, Cheng, Donghang, Yang, Yanwen, Kingsley, Charles, Kulp, Adam, Kleinerman, Eugenie, Gordon A, Nancy. Epigenetic modulation of NK cells to improve tumor trafficking and enhance therapeutic efficacy against osteosarcoma. AACR Annual Meeting 2023, 2023. e-Pub 2023.
- Zheng, Y, Gordon, N, Nancy. BRD4 Regulates Gemcitabine Efficacy by Modulating Autophagy Activity in Osteosarcoma Cells. Keynote Symposium, 2023. e-Pub 2023.
- Livingston, A, Conley, P, Somaiah, N, Araujo, D, Ratan, R, Posey, K, Benjamin, R, Patel, S, Bitar D, Najat, Harrison, Douglas J, Gorlick, Richard, Wang, Wei-Lien, Amini, Behrang, Gordon, Gill NA, Benjamin J. A Phase 1/2 Trial of Gemcitabine, Docetaxel, and Hydroxychloroquine in Advanced/Metastatic Osteosarcoma: Results of Phase 1. 2022 CTOS Annual Meeting, 2022. e-Pub 2022.
- Livingston, Andrew J, Conley, Paul A, Somaiah, Neeta, Araujo, Dejka, Ratan, Ravin, Posey, Kristi K, Benjamin, Robert S, Patel, Shreyaskumar, Bitar D, Najat, Harrison, Douglas J, Gorlick, Richard, Wang, Wei-Lien, Amini, Behrang, Gordon, Nancy, Gill, Benjamin J. A Phase 1/2 Trial of Gemcitabine, Docetaxel, and Hydroxychloroquine in Advanced/Metastatic Osteosarcoma: Results of Phase 1. 2022 CTOS Annual Meeting, 2022. e-Pub 2022.
- Rupp Anjier A, Gordon N. Low-Dose Aerosolized Gemcitabine Modulates the Tumor Microenvironment and Increases NK Cell Efficacy Against Osteosarcoma Lung Metastasis (Poster Abstract). 2022 Keystone Symposia Conference, 2022. e-Pub 2022.
- Stefan, Kirsten, Cerda Carolyn DL, Douglas H, Nancy G, Amer N. CD24-Specific CAR T cell therapy for Osteosarcoma. SITC Annual Meeting 2020, 2020. e-Pub 2020.
- Gordon N, Kleinerman ES, Sheshadri A, Blanco D, Yedururi S, Morari A, Gill JB, Harrison D, Herzog CE, Livingston JA, Benjamin RS, Gorlick R, Mireles ME, Kawedia JD, Daw NC. A Phase I Trial of Aerosol Gemcitabine for the Treatment of Patients with Solid tumors and lung Metastases. ASCO Virtual Annual Meeting, 2020. e-Pub 2020.
- Hennessy M, Felix S, Wahba A, Kivimae S, Miyama T, Cabrera M, Segura MG, Zalevsky J, Overwijk W, Gordon N. A potential immunotherapeutic approach for the treatment of Osteosarcoma. AACR Annual Meeting 2019, Atlanta, GA, 2019. e-Pub 2019.
- Hennessy M, Felix S, Wahba A, Kivimae S, Miyama T, Cabrera M, Segura MG, Zalevsky J, Overwijk W, Gordon N. A potential immunotherapeutic approach for the treatment of Osteosarcoma. AACR Annual Meeting 2019, Atlanta, GA, 2019. e-Pub 2019.
- Nehme G, Felix K, Wahba A, Holloman M, Fandino M, Santiago O'Fairill J, Kleinerman E, Gordon N. Phosphorylated HSP27 to predict the role of Gemcitabine induced autophagy in osteosarcoma. Keystone Symposia Conference, Santa Fe, NM, 2019. e-Pub 2019.
- Nehme G, Felix K, Wahba A, Holloman M, Fandino M, Santiago O'Fairill J, Kleinerman E, Gordon N. Phosphorylated HSP27 to predict the role of Gemcitabine induced autophagy in osteosarcoma. Keystone Symposia Conference, Santa Fe, NM, 2019. e-Pub 2019.
- Dao L, Foglesong J, Batth I, Zaky W, Gill JB, Liu D, Albert A, Gordon N, Huh W, Harrison D, Herzog C, Kleinerman E, Gorlick R, Daw NC, Li S. Enumeration of cell surface vimentin positive cells as a method of detecting tumor cells in pediatric patients with sarcoma. CTOS 2019 Annual Meeting, 2019. e-Pub 2019.
- Dao L, Foglesong J, Batth I, Zaky W, Gill JB, Liu D, Albert A, Gordon N, Huh W, Harrison D, Herzog C, Kleinerman E, Gorlick R, Daw NC, Li S. Enumeration of cell surface vimentin positive cells as a method of detecting tumor cells in pediatric patients with sarcoma. CTOS 2019 Annual Meeting, 2019. e-Pub 2019.
- Nehme G, Felix K, Wahba A, Fandino D, Gordon N. Autophagy and HSP27. A potential link to define autophagy fate in Osteosarcoma. AACR Annual Meeting, 2018. e-Pub 2018.
- Nehme G, Felix K, Wahba A, Fandino D, Gordon N. Autophagy and HSP27. A potential link to define autophagy fate in Osteosarcoma. AACR Annual Meeting, 2018. e-Pub 2018.
- Dhupkar P, Kleinerman ES, Gordon N. Targeting the PD-1/PDL-1 Signaling Pathway for the Treatment of Osteosarcoma Lung Metastasis. Connective Tissue Oncology Society, November 9-12, 2016, Lisbon, Portugal, 2016. e-Pub 2016.
- Dhupkar P, Kleinerman ES, Gordon N. Targeting the PD-1/PDL-1 Signaling Pathway for the Treatment of Osteosarcoma Lung Metastasis. Connective Tissue Oncology Society, November 9-12, 2016, Lisbon, Portugal, 2016. e-Pub 2016.
- Santiago-O'Farrill J, Hollomon M, Gordon N, Kleinerman E. HSP27 as a Potential Factor to Determine the Fate of Gemcitabine-Induced Autophagy in osteosarcoma: Survival vs. Death. 2016 Keystone Symposia Conference, Autophagy: Molecular and Physiological Mechanisms, Whistler, British Columbia, 2016. e-Pub 2016.
- Santiago-O'Farrill J, Hollomon M, Gordon N, Kleinerman E. HSP27 as a Potential Factor to Determine the Fate of Gemcitabine-Induced Autophagy in osteosarcoma: Survival vs. Death. 2016 Keystone Symposia Conference, Autophagy: Molecular and Physiological Mechanisms, Whistler, British Columbia, 2016. e-Pub 2016.
- Moonat HR, Huang G, Gordon N, Kleinerman E. A combination approach targeting osteosarcoma cells in vitro using IL-11Ra CAR T-cells with anti-PD-1 Blockade. ASHPO 2016 Annual Meeting, 2016. e-Pub 2016.
- Moonat HR, Huang G, Gordon N, Kleinerman E. A combination approach targeting osteosarcoma cells in vitro using IL-11Ra CAR T-cells with anti-PD-1 Blockade. ASHPO 2016 Annual Meeting, 2016. e-Pub 2016.
- Livingston JA, Santiago-O'Farrill J, Tsai JW, Lu Z, Bast R, Wang WL, Gordon N, Kleinerman E. Heat shock protein 27 as a predictor of autophagic fate in chemotherapy-induced autophagy in osteosarcoma. CTOS 20th Annual Meeting, oral presentation, November 7, 2015 in Salk Lake City, Utah, 2015. e-Pub 2015.
- Dhupkar MS, Yu L, Kleinerman ES, Gordon N. Immune modulation through targeting PD-1/PDL-1 signaling pathway for the treatment of osteosarcoma lung metastastes. The Society for Immunotherapy of Cancer (SITC) 30th Annual Meeting, National Harbor, MD, 2015. e-Pub 2015.
- Dhupkar MS, Yu L, Kleinerman ES, Gordon N. Immune modulation through targeting PD-1/PDL-1 signaling pathway for the treatment of osteosarcoma lung metastastes. The Society for Immunotherapy of Cancer (SITC) 30th Annual Meeting, National Harbor, MD, 2015. e-Pub 2015.
- Livingston JA, Santiago-O'Farrill J, Tsai JW, Lu Z, Bast R, Wang WL, Gordon N, Kleinerman E. Heat shock protein 27 as a predictor of autophagic fate in chemotherapy-induced autophagy in osteosarcoma. CTOS 20th Annual Meeting, oral presentation, November 7, 2015 in Salk Lake City, Utah, 2015. e-Pub 2015.
- Gordon N, Santiago-O'Farrill JM, Hollomon M, Kleinerman ES. Heat Shock protein 27 as biomarker predicting the role of chemotherapy-induced autophagy on drug sensitivity. 7th International Conference on Tumor Microenvironment: Progression, Therapy & Prevention, Tel Aviv, Israel, 2015. e-Pub 2015.
- Santiago-O’Farrill JM, Hollomon M, Kleinerman ES, Gordon N. HSP27 as a potential factor to determine the fate of Gemcitabine- induced autophagy in osteosarcoma: Survival vs. death. AACR Annual Meeting 2015, Philadelphia, PA April 18-22, 2015. e-Pub 2015.
- Santiago-O'Farrill JM, Hollomon M, Kleinerman ES, Gordon N. HSP27 as a potential factor to determine the fate of Gemcitabine- induced autophagy in osteosarcoma: Survival vs. death. Phoenix, AZ May 6-9 (#743). ASPHO Annual Meeting, 2015. e-Pub 2015.
- Dhupkar PM, Yu L, Kleinerman ES, Gordon N. Immune modulation of Natural Killer cell adoptive transfer for the treatment of Osteosarcoma lung metastasis: Targeting the PD-1/ PDL-1 signaling pathway. AACR Tumor Immunology and Immunotherapy: A New Chapter, December 1-4, 2014, Orlando, FL, 2014. e-Pub 2014.
- Satelli A, Xia X, Brownlee Z, Ludwig J, Torres K, Somaiah N, Gordon N, Bitar ND, Zweilder-McKay P, Tomaras M, Foglesong J, Kleinerman ES, Li S. Universal Marker for Circulating Tumor Cell Detection from Pediatric-Type of Tumors. ASPHO 27th Annual Meeting May 14th-17th, 2014, 2014. e-Pub 2014.
- Santiago-O’Farrill J, Hollomon M, Kleinerman ES, Gordon N. HSP27 as a potential Factor to Determine the Fate of Gemcitabine-Induced Autophagy in Osteosarcoma: Survival vs. Death. Lost Pines Conference 2014. Cell Death and Metabolism, November 21-22, 2014. e-Pub 2014.
- Gordon N, Daw NC, Anderson PM, Guma S, H-C C, Zinner R, Subbiah V, Hajair J, Kleinerman ES, Naing A. Aerosol interleukin-2 for the treatment of patients ≥12 years old with lung metastases from osteosarcoma: a phase I trial. SITC 29th Annual Meeting, November 7-9, 2014, National Harbor, MD, 2014. e-Pub 2014.
- Gordon N, Daw N, Anderson P, Guma S, H-C C, McQuinn LM, Hein JP, Zinner R, Kleinerman ES, Naing A. Aerosol Interleukin-2 for the treatment of patients ≥ 12 years old with Osteosarcoma lung disease: a phase I/II study. AACR Annual Meeting 2014, April 5-9 in San Diego, CA, 2014. e-Pub 2014.
- Satelli A, Xia X, Brownlee Z, Ludwig J, Torres K, Somaiah N, Gordon N, Bitar ND, Zweilder-McKay P, Tomaras M, Foglesong J, Kleinerman ES, Li S. Universal Marker for Circulating Tumor Cell Detection from Pediatric-Type of Tumors. ASPHO 27th Annual Meeting May 14th-17th, 2014, 2014. e-Pub 2014.
- Gordon N, Daw N, Anderson P, Guma S, H-C C, McQuinn LM, Hein JP, Zinner R, Kleinerman ES, Naing A. Aerosol Interleukin-2 for the treatment of patients ≥ 12 years old with Osteosarcoma lung disease: a phase I/II study. AACR Annual Meeting 2014, April 5-9 in San Diego, CA, 2014. e-Pub 2014.
- Gordon N, Daw NC, Anderson PM, Guma S, H-C C, Zinner R, Subbiah V, Hajair J, Kleinerman ES, Naing A. Aerosol interleukin-2 for the treatment of patients ≥12 years old with lung metastases from osteosarcoma: a phase I trial. SITC 29th Annual Meeting, November 7-9, 2014, National Harbor, MD, 2014. e-Pub 2014.
- Naing A, Anderson P, Guma S, H-C C, McQuinn LM, Hein JP, Zinner R, Kleinerman ES, Gordon N. Evaluation of feasibility and safety of Aerosol IL-2 in sarcoma patients with lung metastases for future combination therapy with infused Natural Killer cells. 28th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), National Harbor, MD, 2013. e-Pub 2013.
- Gordon N, Anderson P, Guma S, H-C C, McQuinn LM, Hein JP, Zinner R, Kleinerman ES, Naing A. Feasibility and safety of aerosol IL-2 in patients with lung metastases for future combination therapies for the treatment of Osteosarcoma lung metastases. Pediatric Cancer at the Crossroads: Translating Discovery Into Improved Outcomes, San Diego, CA, 2013. e-Pub 2013.
- Gordon N, Anderson P, Guma S, Chien HC, McQuinn LM, Hein JP, Zinner R, Kleinerman ES, Naing A. Clinical evaluation of aerosol IL-2 in patients with lung metastases to test feasibility and safety for future combination therapy using infused natural killer cells. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics poster presentation, Boston MA, 2013. e-Pub 2013.
- Santiago-O'Farrill JM, Hollomon M, Kleinerman ES, Gordon N. Autophagy as a mechanism implicated in Osteosarcoma Resistance to Gemcitabine. AACR-NCI-EORTIC International Conference on Molecular Targets and Cancer Therapeutics poster presentation, Boston, MA, 2013. e-Pub 2013.
- Gordon N, Hollomon M, H-C C, O'Farril JS, Kleinerman E. The microenvironment plays an important role in the ability of aerosol Gemcitabine and Liposomal 9-Nitrocamptothecin to elicit therapeutic effect on Osteosarcoma lung metastases. American Society for Cancer Research Special Conference - Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy, Orlando, FL, 2011. e-Pub 2011.
- Gordon N, Koshkina N, Kleinerman ES. Fas ligand is critical to the therapeutic efficacy of aerosol Gemcitabine against Osteosarcoma lung metastases. American Association for Cancer Research 98th Annual Meeting, 2007. e-Pub 2007.
- Gordon N, Koshkina N, Kleinerman ES. Fas ligand is critical to the therapeutic efficacy of aerosol Gemcitabine against Osteosarcoma lung metastases. American Association for Cancer Research 98th Annual Meeting, 2007. e-Pub 2007.
- Gordon N, Carola A, Hawkins HS, Doherty DK, Inwards CY, Munsell M, Koshkinia N, Kleinerman ES. Fas expression in osteosarcoma lung metastasis is correlated with chemotherapy prior to surgery. American Association for Cancer Research 96th Annual Meeting, 2005. e-Pub 2005.
- Gordon N, Carola A, Hawkins HS, Doherty DK, Inwards CY, Munsell M, Koshkinia N, Kleinerman ES. Fas expression in osteosarcoma lung metastasis is correlated with chemotherapy prior to surgery. American Association for Cancer Research 96th Annual Meeting, 2005. e-Pub 2005.
- Gordon N, Koshkina N, Worth L, Kleinerman ES. Fas expression is critical to the metastatic potential of murine Osteosarcoma cell line and can be used as a therapeutic target. American Association for Cancer Research 95th Annual Meeting, 2004. e-Pub 2004.
- Gordon N, Koshkina N, Worth L, Kleinerman ES. Fas expression is critical to the metastatic potential of murine Osteosarcoma cell line and can be used as a therapeutic target. American Association for Cancer Research 95th Annual Meeting, 2004. e-Pub 2004.
- Zheng Yan, Gordon NB. BRD4 Regulates Gemcitabine Efficacy by Modulating Autophagy Activity in Osteosarcoma Cells. Autophagy and Neurodegeneration: Mechanisms to Therapies.
- Zheng Yan, Gordon NB, Shi Y, Kleinerman ES, Maegawa S. BRD4 Regulates Gemcitabine Efficacy by Modulating Autophagy Activity in Osteosarcoma Cells. Keystone Symposia.
- Kleinerman E, Gordon NB. A Novel Dendritic Cell Vaccine Targeting CD70 for Osteosarcoma Lung Metastases. MIB Agents.
- Livingston J, Gill J, Conley A, Somaiah N, Araujo D, Ratan R, Ravi V, Robert Benjamin AZ, Patel S, Daw NC, Harrison D, Gorlick R, Otto T, Lin H, Wang W, Amini B, Kleinerman E, Gordon N. A Phase 1/2 Trial of Gemcitabine, Docetaxel, and Hydroxychloroquine in Advanced Metastatic Osteosarcoma: Final Results. Connective Tissue Oncology Society.
- Livingston J, Gill J, Conley A, Somaiah N, Araujo D, Ratan R, Ravi V, Robert Benjamin AZ, Patel S, Daw NC, Harrison D, Gorlick R, Otto T, Lin H, Wang W, Amini B, Kleinerman E, Gordon N. A Phase 1/2 Trial of Gemcitabine, Docetaxel, and Hydroxychloroquine in Advanced Metastatic Osteosarcoma: Final Results. European Society for Medical Oncology.
- Gordon NB, Ramakrishnan Ramya, Anjier Ariana R, Rav Emily S, Zheng Yan, Acharya Sunil, Basar Rafet, Rezvani Katy, Wang Wei-Lien, Bitar D Najat, Wani Khalida M, Ingram Davis R, Gopalakrishnan Vidya, Kleinerman Eugenie S. IL -17A IL-17A as a potential cytokine that modulates cytotoxicity of CD 70-directed Chimeric Antigen Receptor Natural Killer (CAR NK) cells against Osteosarcoma. SITC 2024 Speaker Management System.
- Estrada V, Gordon NB, Kleinerman ES. Pramlintide Enhances NK Cell Cytotoxicity Against Osteosarcoma Cells. Annual Biomedical Research Conference for Minoritized Scientists (ABRCMS) 2024.
- Anjier A, Gordon NB, Kleinerman ES. Entinostat enhances NK cell efficacy against osteosarcoma lung metastases by improving cytokine production, trafficking, persistence and cytotoxicity. SITC 39th Annual Meeting.
- Ramakrishnan R, Gordon NB. Identifying the potential mechanism of cytotoxicity mediated by CD70 directed Chimeric Antigen Receptor Natural Killer (CAR NK) cells against osteosarcoma. SITC Spring Scientific.
- Ramakrishnan R, Gordon NB, Anjier A, Acharya S, Rezvani K, Zheng Y, Bitar D N, Gopalakrishnan V, Hollomon M, Kleinerman ES. Identifying Potential Mechanism of Cytotoxicity Mediated by CD70 Car NK Cells Against Osteosarcoma. Fellows' Research Showcase.
- Anjier A, Zheng Y, Yang Y, Estrada VB, Wang H, Wang Q, Bankson J, Tan L, Tran B, Martinez S, Kleinerman E, Gordon AN. The anti-diabetic drug Pramlintide modulates osteosarcoma tumor metabolism and improves NK cell therapy. AACR Rare Cancers Conference.
- Zheng Y, Anjier A, Wang H, Hollomon M, Kleinerman ES, Gordon N. Hsp27 Mediates sensitivity to Gemcitabine through Mitophagy Regulation in Osteosarcoma. AACR Rare Cancers Conference.
Book Chapters
- Kiany, S, Harrison, DJ, Gordon, N. The Histone Deacetylase Inhibitor Entinostat/Syndax 275 in Osteosarcoma, 75-83, 2020.
- Gordon N, Felix K, Daw Bitar N. Aerosolized Chemotherapy for Osteosarcoma. In: Current Advances in Osteosarcoma. Advances in Experimental Medicine and Biology. 2nd. Springer, Cham, 2020.
- Kiany S, Harrison D, Gordon N. The Histone Deacetylase Inhibitor Entinostat/Syndax 275 in Osteosarcoma. In: Current Advances in Osteosarcoma. Advances in Experimental Medicine and Biology. 2nd. Springer, Cham, 2020.
- Gordon N. Osteosarcoma and Autophagy. In: Current Advances in Osteosarcoma. Advances in Experimental Medicine and Biology. 2nd. Springer, Cham, 2020.
- Nehme, G, Gordon, N. Autophagy in osteosarcoma, 167-175, 2020.
- Dhupkar P, Gordon N. Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy. In: Adv Exp Med Biol Series, Immunotherapy. 1st. Springer, 33-51, 2017.
- Kiany S, Gordon N. Aerosol Delivery of Interleukin-2 in Combination with Adoptive Transfer of Natural Killer Cells for the treatment of Lung Metastasis: Methodology and Effect. In: Methods Mol Biol. 1st. Springer, 285-95, 2016.
- Santiago O'Farrill J, Gordon N. Autophagy in Osteosarcoma. In: Current Advances in Osteosarcoma. 1st. Springer, 147-160, 2014.
- Gordon N, Kleinerman ES. The Role of Fas/FasL in the Metastatic Potential of Osteosarcoma and Targeting this Pathway for the Treatment of Osteosarcoma Lung Metastases. In: Pediatric and Adolescent Osteosarcoma. 1st. Springer, 497-508, 2010.
Patient Reviews
CV information above last modified September 11, 2026